Skip to content
Screener

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
CTO
Citius Oncology, Inc.CTOR
$15.13M+299%
Vor Biopharma logo
Vor BiopharmaVOR
$74.87M+12,455%

Other financials

Income statement

See full
Revenue-
Operating income-$57.3M+24.5%
Net income-$53.7M+23.3%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$78.6M+8.0%
Total debt$2.1M+36.3%
Total equity$408.7M-30.8%
Total assets$363.8M-30.1%

Cash flow

See full
Operating cash flow-$38.2M+33.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.14B+165%
Enterprise value$1.06B+196%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio8.4×-1.4×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336717
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net cash provided by investing activities73,09290,206
Financing activities:
Issuance of common stock under equity-based compensation plans1,480373
Net cash provided by financing activities1,480373
Net decrease in cash and cash equivalents(9,692)(10,185)
Cash and cash equivalents at beginning of period88,33283,005
Cash and cash equivalents at end of period$78,640$72,820
Non-cash investing and financing activities and supplemental disclosure of cash flow information:

Item 1. Financial Statements.

FAQ

What is Cullinan Therapeutics, Inc.'s financing cash flow?
Cullinan Therapeutics, Inc. (CGEM) reported financing cash flow of $1.1M in Q2 2026.
How has Cullinan Therapeutics, Inc.'s financing cash flow changed year-over-year?
Cullinan Therapeutics, Inc.'s financing cash flow increased by 194.9% year-over-year, from $373K to $1.1M.
What is the long-term trend for Cullinan Therapeutics, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s financing cash flow has grown at a -74.8% compound annual growth rate (CAGR), from $268.78M to $1.09M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Cullinan Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude